InMode Ltd.
NASDAQ Global Select•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Moshe Mizrahy
- Full Time Employees
- 581
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Tavor Building Yokne'am Israel 2069206
- IPO Date
- Aug 8, 2019
- CIK
- 0001742692
- Website
- inmodemd.com
- Similar Companies
- Business
- InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
Company News
InMode to Report Third Quarter 2024 Financial Results and Hold Conference Call on October 30, 2024
Stock Picks From Seeking Alpha's September 2024 New Analysts
InMode Announces Departures of President of North America, Chief Medical Officer and VP of Sales USA as Part of a Global Reorganization Strategy
Should Value Investors Buy InMode (INMD) Stock?
InMode Offers High Risk-Reward Opportunity Amid New Products And Rate Cuts (Rating Upgrade)
Are Investors Undervaluing InMode (INMD) Right Now?
InMode Announces Share Repurchase Program of Up to 7.68 Million Shares
InMode Stock: An Inverse Bubble Caused By Short-Term Trouble
InMode to Present at 2024 Baird Global Healthcare Conference
InMode to Present at Upcoming Investor Conferences
InMode Ltd. (INMD) Q2 2024 Earnings Call Transcript
InMode (INMD) Q2 Earnings and Revenues Top Estimates
InMode Reports Second Quarter 2024 Financial Results; Quarterly Revenue of $86.4M Represents 36.5% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet delivered) of $102.6M
InMode Introduces IgniteRF The Complete Minimally Invasive Soft Tissue Contraction Platform
Analysts Estimate InMode (INMD) to Report a Decline in Earnings: What to Look Out for
DOMA Perpetual Sends Letter to the Board of Directors of InMode Urging the Execution of a 40% Tender Offer
Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling
InMode to Report Second Quarter 2024 Financial Results and Hold Conference Call on Aug. 1, 2024
3 MedTech Stocks to Buy for Healthy Gains
InMode: Reversing Previous Shareholder Dilution With Buybacks